<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00692120</url>
  </required_header>
  <id_info>
    <org_study_id>2006-0013</org_study_id>
    <nct_id>NCT00692120</nct_id>
  </id_info>
  <brief_title>Clinical Approaches to Correcting Vitamin D Inadequacy and Maintaining Adequacy</brief_title>
  <acronym>D2/D3</acronym>
  <official_title>Clinical Approaches to Correcting Vitamin D Inadequacy and Maintaining Adequacy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vitamin D is available in two forms, vitamin D2 and vitamin D3. It has previously been
      assumed that these two forms maintain blood vitamin D equally. However, this may not be the
      case. This study will evaluate whether D2 and D3 produce equal elevation of blood vitamin D.
      Additionally, it will evaluate whether once per month vitamin D dosing is as effective in
      maintaining blood vitamin D levels as daily dosing.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome measure is change in 25OHD with various D2 and D3 dosing regimens.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine whether once monthly vitamin D2 or D3 dosing is as effective as daily dosing in attainment, and subsequent maintenance, of 25OHD status</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delineate the effect of these vitamin D regimens on other parameters of skeletal relevance</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Vitamin D Inadequacy</condition>
  <condition>Vitamin D Deficiency</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Cholecalciferol (vitamin D3)</intervention_name>
    <description>50,000 IU once monthly for 12 months</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ergocalciferol (vitamin D2)</intervention_name>
    <description>oral capsule 50,000 IU once monthly for 12 months</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ergocalciferol (vitamin D2)</intervention_name>
    <description>oral capsule 1600 IU once daily for 12 months</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Cholecalciferol (vitamin D3)</intervention_name>
    <description>oral capsule 1600 IU once daily for 12 months</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral placebo capsule once daily for 12 months</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Community dwelling men and women age ≥ 65 years.

          2. Able and willing to sign informed consent.

          3. Serum 25OHD concentration ≥ 10 and less than 60 ng/ml by HPLC.

          4. Willing to avoid use of cod-liver oil and non-study vitamin D supplementation;
             standard multiple vitamins containing ≤ 400 IU used no more than once daily will be
             allowed

        Exclusion Criteria:

          1. Current hypercalcemia (serum calcium &gt; 10.5 mg/dl) or untreated primary
             hyperparathyroidism.

          2. History of nephrolithiasis.

          3. Screening 25OHD concentration ≥ 60 ng/ml.

          4. Baseline 24-hour urine calcium &gt; 250 mg if female, &gt; 300 mg if male.

          5. Known risk factors for hypercalcemia, e.g., malignancy, tuberculosis, sarcoidosis,
             Paget's disease

          6. History of any form of cancer within the past five years with the exception of
             adequately treated squamous cell or basal cell skin cancer.

          7. Renal failure defined as a calculated creatinine clearance (Cockroft-Gault method) ≤
             25 ml/minute

          8. Severe end-organ disease, e.g., cardiovascular, hepatic, hematologic, pulmonary, etc.,
             which may limit ability to complete the study

          9. Known malabsorption syndromes, e.g., celiac disease, radiation enteritis, active
             inflammatory bowel disease, etc.

         10. Use of medications known to alter bone turnover including bisphosphonates, estrogen,
             selective estrogen receptor modulators, PTH, testosterone or calcitonin

         11. Vitamin D intake greater than 5,000 IU daily

         12. Treatment with any active metabolites of vitamin D within six months of screening

         13. Treatment with any drug which may interfere with vitamin D metabolism, e.g.,
             phenobarbital, phenytoin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neil Binkley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin - Institute on Aging</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UW Osteoporosis Clinical and Research Program</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 2, 2008</study_first_submitted>
  <study_first_submitted_qc>June 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2008</study_first_posted>
  <last_update_submitted>October 1, 2015</last_update_submitted>
  <last_update_submitted_qc>October 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

